Juan Manuel Carreño
A5015092469- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Influenza Virus Research Studies
- Respiratory viral infections research
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
- Virology and Viral Diseases
- COVID-19 and healthcare impacts
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- COVID-19 epidemiological studies
- vaccines and immunoinformatics approaches
- Long-Term Effects of COVID-19
- Viral Infections and Outbreaks Research
- COVID-19 Impact on Reproduction
- Cancer Immunotherapy and Biomarkers
- COVID-19 and Mental Health
- Animal Disease Management and Epidemiology
- interferon and immune responses
- Complement system in diseases
- Immune Response and Inflammation
- Immune responses and vaccinations
Icahn School of Medicine at Mount Sinai
2020-2025
Tisch Cancer Institute
2024
Mount Sinai Hospital
2023
Kantonsspital St. Gallen
2016-2017
Responses of Seropositive Persons to a Single SARS-CoV-2 Vaccine Some persons who have recovered from Covid-19 antibodies the spike protein SARS-CoV-2. In 43 such had receive...
Immune responses at the respiratory mucosal interface are critical to prevent infections but it is unclear what extent antigen specific secretory IgA (SIgA) antibodies induced by mRNA vaccination in humans. Here we analyze paired serum and saliva samples from patients with without prior coronavirus disease 2019 (COVID-19) multiple time points pre post severe acute syndrome 2 (SARS-CoV-2) vaccination. Our results suggest SIgA impacted pre-existing immunity. Indeed, a minimal response...
Although mRNA vaccines encoding the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevent COVID-19, emergence new viral variants jeopardizes their efficacy. Here, we assessed immunogenicity and protective activity historical (mRNA-1273, designed for Wuhan-1 protein) or modified (mRNA-1273.351, B.1.351 Moderna in 129S2 K18-hACE2 mice. Mice were immunized with either high-dose low-dose formulations vaccines, where vaccination modeled suboptimal immune responses....
Abstract Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have been reported in immune-compromised individuals and people undergoing immune-modulatory treatments. Although intrahost evolution has documented, direct evidence of subsequent transmission continued stepwise adaptation is lacking. Here we describe sequential persistent SARS-CoV-2 three that led to the emergence, forward transmission, a new Omicron sublineage, BA.1.23, over an eight-month period....
It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies. Here, we analyzed the kinetics and durability of humoral responses SARS-CoV-2 infection vaccination using >8,000 longitudinal samples collected over a 3-year period in New York City. Upon primary immunization, participants with pre-existing mounted higher antibody faster achieved steady-state titers than naive individuals....
Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high capacity for rapid development. Generation of universal influenza virus the potential to elicit long-lasting, broadly cross-reactive immune responses is necessity reducing influenza-associated morbidity and mortality. Here we focus on development B based lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform. We evaluate candidates different target antigens that afford protection against...
Combined vaccine formulations targeting not only hemagglutinin but also other influenza virus antigens could form the basis for a universal that has potential to elicit long-lasting, broadly cross-reactive immune responses. Lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccines can be utilized efficiently target multiple with single vaccine. Here, we assessed immunogenicity and protective efficacy of nucleoside-modified mRNA-LNP contain four A group 2 (hemagglutinin stalk,...
Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S an inactivated egg-based recombinant Newcastle virus vaccine expressing the spike (S) protein severe acute respiratory syndrome 2 (SARS-CoV-2). It's being developed by public sector manufacturers Thailand, Vietnam, Brazil; herein are initial results from Thailand.This phase 1 stage a randomised, dose-escalation, observer-blind, placebo-controlled, 1/2 trial was...
There is still a need for safe, efficient, and low-cost coronavirus disease 2019 (COVID-19) vaccines that can stop transmission of severe acute respiratory syndrome 2 (SARS-CoV-2). Here we evaluated vaccine candidate based on live recombinant Newcastle virus (NDV) expresses stable version the spike protein in infected cells as well surface viral particle (AVX/COVID-12-HEXAPRO, also known NDV-HXP-S). This be grown embryonated eggs at low cost, similar to influenza vaccines, it administered...
The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1–3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling >15,000 longitudinal blood nasal samples 540 participants the using 14 distinct assays. These unbiased analyses identify cellular molecular signatures present within 72 h hospital admission that...
Influenza A viruses (IAVs) of subtype H9N2 have reached an endemic stage in poultry farms the Middle East and Asia. As a result, human infections with avian been increasingly reported. In 2017, virus was isolated for first time from Egyptian fruit bats (Rousettus aegyptiacus). Phylogenetic analyses revealed that bat is descended common ancestor dating back centuries ago. However, H9 N2 sequences appear to be genetically similar current IAVs, suggesting recent reassortment events. These...
Germinal centers (GC) are microanatomical lymphoid structures where affinity-matured memory B cells and long-lived bone marrow plasma primarily generated. It is unclear how the maturation of within GC impacts breadth durability cell responses to influenza vaccination in humans. We used fine needle aspiration draining lymph nodes longitudinally track antigen-specific seasonal vaccination. Antigen-specific persisted for at least 13 wk after two out seven individuals. Monoclonal antibodies...
BackgroundHighly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed. However, the emergence of viral variants that are more infectious than earlier SARS-CoV-2 strains is concerning. Several these potential to partially escape neutralizing antibody responses, warranting continued immune-monitoring.MethodsWe used a panel 30 post-mRNA vaccination sera determine neutralization and RBD spike binding activity number emerging variants. The...
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed in record time and show excellent efficacy effectiveness disease 2019 (COVID-19). However, currently approved vaccines cannot meet the global demand. In addition, none of used is administered intranasally to potentially induce mucosal immunity. Here, we tested safety immunogenicity a second-generation SARS-CoV-2 vaccine that includes stabilized spike antigen can be intranasally. The based on live...
Production of affordable coronavirus disease 2019 (COVID-19) vaccines in low- and middle-income countries is needed. NDV-HXP-S an inactivated egg-based Newcastle virus (NDV) vaccine expressing the spike protein severe acute respiratory syndrome 2 (SARS-CoV-2) Wuhan-Hu-1. The was stabilized incorporated into NDV virions by removing polybasic furin cleavage site, introducing transmembrane domain cytoplasmic tail fusion NDV, six prolines for stabilization prefusion state. Vaccine production...
To understand reinfection rates and correlates of protection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we established eight different longitudinal cohorts in 2020 under the umbrella PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2)/SPARTA (SARS SeroPrevalence And Respiratory Tract Assessment) studies. Here, describe PARIS/SPARTA cohorts, harmonized assays analysis that are performed across as well case definitions SARS-CoV-2 infection have been by team...